Arcellx is a development-stage biotechnology company pioneering the field of cell therapy to treat oncology and autoimmune diseases. Arcellx's novel synthetic binding scaffold, the D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts). Its lead program is a BCMA-targeting ddCAR product candidate called anitocabtagene autoleucel or “anito-cel” (formerly, CART-ddBCMA), which is currently being evaluated in our pivotal Phase 2 iMMagine-1 and the Phase 3 iMMagine-3 trials in patients with relapsed or refractory multiple myeloma (rrMM) with Best-in-class potential.

Structure is a clinical stage global biopharmaceutical company developing novel oral small molecule therapeutics to treat a wide range of chronic diseases with unmet medical need. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (“GPCRs”). Structure's most advanced product candidate to date is aleniglipron, also known as GSBR-1290, an oral small molecule selective glucagon-like-peptide-1 receptor (“GLP-1R”) agonist currently in two Phase 2 clinical trials for the treatment of obesity, overweight and related conditions.

Viela Bio is dedicated to the development and commercialization of novel, life-changing medicines for patients with a wide range of autoimmune and severe inflammatory diseases. The team is comprised of passionate, talented, world-class leaders with diverse experience in the autoimmune disease space and our research focuses on well-established critical biological pathways shared across multiple indications. The team believe that the approach – which targets the underlying molecular pathogenesis of the disease – enables Viela Bio to develop more precise therapies, identify patients more likely to respond to treatment and pursue multiple indications for each of their product candidates.

Immunocore a leading T cell receptor (TCR) biotechnology company, focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases, who's most advanced therapeutic programmes are focused on oncology, and also has programmes in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programmes in development and its lead programme, tebentafusp (IMCgp100), which has been granted Fast Track Designation by the US Food & Drug Administration, is in pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Immunocore's partners include Genentech, GlaxoSmithKline, AstraZeneca, Eli Lilly, and the Bill and Melinda Gates Foundation.

Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics on a platform driven by scientific pioneers and experienced company builders. Based on the available genetic information, the company develops new medicines that provide protection against severe diseases through mimicking protective mutations.

Erasca's mission is embedded in its name: To erase cancer. Energized by recent scientific discoveries in drugging various biological drivers of cancer, Erasca is advancing multiple programs that shut down key cancer pathways in order to solve oncology’s hardest problems. Erasca is also pursuing additional pipeline expansion opportunities through academic and biopharmaceutical collaborations. Founded in 2018 and headquartered in San Diego, Erasca has raised more than $260 million in financing from investors who share the company’s bold mission.

Frontera Therapeutics is an AAV gene therapy company with the mission to establish the low cost and scalable platform, to develop and produce high quality and affordably priced rAAV therapies for the global market.

Illumina Ventures is an independently managed firm focused on early-stage companies that are pioneering new applications of genomics and enabling precision medicine, who invest in life science tools, clinical diagnostics, therapeutics, and other opportunities to improve human health.

CStone Pharmaceuticals is a clinical stage biopharmaceutical company devoted to the development of innovative drugs. With a broad pipeline, the company engages in the development of cancer therapeutics with a special focus on immuno-oncology based combination therapies. All members of the management team are seasoned executives from top multinational pharmaceutical companies. CStone has successfully built up its core competency in clinical development and translational medicine. With an experienced team, a rich pipeline, a robust R&D model, and substantial funding, CStone is well positioned as the partner of choice for multinational pharmaceutical and biotech companies to develop drugs in China and the Asia-Pacific region.

Berry Genomics is a leading biotech company in China which develops and commercializes next generation sequencing based integrated solutions for clinical applications, primarily in genetic testing and oncology testing. Berry Genomics pioneered non-invasive prenatal testing (NIPT) in China and is the leading provider of NIPT in China. Like NIPT, the products and technologies under development at Berry Genomics will address unmet needs of other genetic diseases and cancer. Berry Genomics was successfully listed on China's public market as the first genomics focused company in 2017.

Boyu Capital is a China-focused investment firm which seeks to provide growth capital for fast-growing businesses in Greater China, with focused sectors ranging from Consumer and Retail, Media and Technology, Healthcare as well as Financial Services.

Sherpa Healthcare Partners ("SHP") is a value-oriented, innovation driven healthcare investor focusing predominantly on early stage venture capital investments in Greater China. The SHP team has been well recognized for its expertise and track record in China's healthcare industry.

Creacion Ventures is a healthcare and life sciences focused venture capital fund with an investment mandate in both China and the U.S. The team intends to build biotech and medical companies dominating their respective fields, while investing in highly innovative, early stage companies and supporting their global reach.

Haidilao is a globally leading and fast-growing Chinese cuisine restaurant brand focusing on hot pot cuisine. The brand has become a phenomenon in Chinese cuisine that is synonymous with an unparalleled level of service and dining experience, with nearly 1,000 restaurants operating globally. The brand has been recognized as one of the most popular dine-out options among China’s major restaurant brands.